Profile: Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

24.15USD
1 Aug 2013
Price Change (% chg)

$-0.93 (-3.71%)
Prev Close
$25.08
Open
$25.22
Day's High
$25.22
Day's Low
$22.94
Volume
422,319
Avg. Vol
118,161
52-wk High
$25.24
52-wk Low
$11.82

Search Stocks

ABIOMED, Inc. is a provider of mechanical circulatory support devices. The Company offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets product that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In December 2011, the Company announced a higher flow Impella device, named Impella cVAD. The Company received CE mark approval for Impella cVAD in April 2012.

In addition, the Company is conducting initial patient use trials outside of the United States of the Impella RP. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow and is intended to provide the flow and pressure needed to compensate for right heart failure. In November 2011, the Company announced Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics and potentially improving their quality of life. The Company conducted the initial in man implants of Symphony outside the United States.

Impella 2.5

The Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors. The device is designed primarily for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 2.5 is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute. In November 2011, the Company announced additional analysis of the results from the Protect II study. The Company is conducting USpella, the United States multicenter observational registry collecting clinical data and outcomes for patients supported with Impella 2.5 and 5.0 during elective, urgent and emergent procedures.

Impella 5.0 and Impella LD

The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support. The Impella 5.0 can be implanted through a small incision in the femoral artery in the groin using a guide wire to reach the left ventricle of the heart where it can then be directly deployed to draw blood out of the ventricle, deliver it to the arterial system and perfuse the heart muscle. This function is intended to reduce ventricular work. The Impella 5.0 and Impella LD can pump up to five liters of blood per minute, providing full circulatory support.

AB5000 and BVS 5000

The Company manufactures and sells the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The AB5000 and BVS 5000 systems is the only commercially available cardiac assist devices that are approved by the Food and Drug Administration (FDA) for all indications where heart recovery is the desired outcome, including patients who have undergone cardiac surgery and subsequently develop low cardiac output, or patients who suffer from acute cardiac disorders leading to hemodynamic instability. The Company has developed a Portable Circulatory Support Driver for both in-hospital and out-of-hospital patients. The Portable Driver is designed to support the Company's AB5000 VAD.

AbioCor

The Company's AbioCor implantable replacement heart is a self-contained artificial heart. Designed to sustain the body's circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Patients with advanced age, impaired organ function or cancer are generally ineligible for a heart transplant and are potential candidates to receive the AbioCor implantable heart. AbioCor devices have a life expectancy of 18 to 24 months and can only be implanted in normal to larger sized male patients.

The Company competes with Getinge, Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, CircuLite, Inc., Terumo Heart, Inc. and CardiacAssist Inc.

Company Address

Abiomed Inc

22 Cherry Hill Drive
DANVERS   MA   01923
P: +1978.6461400
F: +1978.7778411

Search Stocks